Clinical Trials Logo
  1. Home
  2. Colorectal Cancer Stage IV
  3. NCT05354817

Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin — Re-Play  

Colorectal Cancer Stage IV Clinical Trial

Official title:
Re-Play: Impact of FOLFIRINOX Chemotherapy in IV Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin

Clinical Trial Summary

The purpose of this work is to verify prospectively what the rate of response after triple chemotherapy with mFOLFIRINOX in patients in IV stage of Colorectal Cancer who have already failed after at least two lines of dual combinations with fluoropyrimidine, oxaliplatin, irinotecan and anti-EGFR if wild-type RAS. Currently at ICESP, patients are frequently re-exposed in third line to double combinations.

Clinical Trial Description

Single-arm phase II study. The chemotherapy regimen with mFOLFIRINOX will be administered every 14 for 4 cycles, after evaluation of tumor response, you can maintain treatment until disease progression. The FOLFIRINOX regimen, as well as the drugs used (oxaliplatin, 5-Fluorouracil, leucovorin and irinotecan) is already indicated in the package insert for the treatment of colorectal cancer. If treatment is discontinued after cycle 4 with the patient responding, for response maximum or unmanageable toxicity, it is suggested to maintain imaging control every 60 days (7-day window) until disease progression. This interval is already commonly used for patients with metastatic disease who are on treatment pause. Treatment in progression of illness will be at the discretion of the treating physician. Cancer patients undergoing chemotherapy routinely perform evaluation of organ functions and CEA, as well as clinical evaluation before each cycle of treatment ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05354817
Study type Interventional
Source Instituto do Cancer do Estado de São Paulo
Contact
Status Recruiting
Phase Phase 2
Start date October 22, 2021
Completion date December 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03594448 - Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients
Active, not recruiting NCT03986541 - AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer
Completed NCT01570452 - Matrilysin Expression in Different Stages of Colorectal Tumors N/A
Recruiting NCT05576896 - Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory Phase 2
Completed NCT04715061 - Impact of Aerobic Exercise on Immune Response and Side Effects of Cancer Treatments N/A
Terminated NCT03149679 - The p53 Colorectal Cancer Trial Phase 2
Completed NCT05550701 - Prognostic Impact of Increased Lymph Node Yield in Colorectal Cancer Patients With Synchronous Distant Metastasis: a Population-based Study of the US Database and a Chinese Registry
Enrolling by invitation NCT04149613 - Predictive and Prognostic Value of Inflammatory Markers and microRNA in Stage IV Colorectal Cancer
Completed NCT04425239 - Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer Phase 2
Completed NCT06329700 - Parenchymal Sparing Hepatectomy in Post-chemotherapy Liver Atrophy
Recruiting NCT05382741 - Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial Phase 2
Recruiting NCT06342440 - Early Detection of Advanced Adenomas and Colorectal Cancer
Not yet recruiting NCT04917276 - Treatment Response Prediction System of mCRC Patients Based on CTC
Not yet recruiting NCT06296056 - Phase I Study of Combined Immune Cell Therapy in Patients With Stage 4 Colorectal Cancer With Metastatic Lesion Who Failed Prior Standard of Care Phase 1
Recruiting NCT04714814 - Mechanisms of Fate Evolution of Colorectal Adenocarcinoma Metastasis
Not yet recruiting NCT05451719 - Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy Phase 2
Completed NCT03031444 - Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis Phase 2/Phase 3
Completed NCT05164419 - Impact de la Marge de résection Sur la Survie à Long Terme et le Taux de récidive Des Patients Atteints de Cancers Colorectaux opérés au CHUS Entre 2006 et 2016 Pour Des métastases hépatiques
Recruiting NCT05171660 - Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer Phase 3
Recruiting NCT05426005 - Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer Phase 1/Phase 2